Форма представления | Статьи в зарубежных журналах и сборниках |
Год публикации | 2016 |
Язык | английский |
|
Габдулхакова Аида Габдрахмановна, автор
|
Библиографическое описание на языке оригинала |
Meijer L. Modulating Innate and Adaptive Immunity by (R)-Roscovitine: Potential Therapeutic Opportunity in Cystic Fibrosis. / Nelson DJ, Riazanski V, Gabdoulkhakova AG, Hery-Arnaud G, Le Berre R, Loaëc N, Oumata N, Galons H, Nowak E, Gueganton L, Dorothée G, Prochazkova M, Hall B, Kulkarni AB, Gray RD, Rossi AG, Witko-Sarsat V, Norez C, Becq F, Ravel D, Mottier D, Rault G. // J Innate Immun. - 2016. - 8(4): P. 330-49. doi: 10.1159/000444256. |
Аннотация |
Journal of innate immunity |
Ключевые слова |
Roscovitine, Seliciclib, TRPC6, CFTR, Corrector, Cystic fibrosis, Infection, Inflammation, Innate immunity, Pseudomonas aeruginosa
|
Название журнала |
J Innate Immun
|
URL |
https://www.karger.com/Article/FullText/444256 |
Пожалуйста, используйте этот идентификатор, чтобы цитировать или ссылаться на эту карточку |
https://repository.kpfu.ru/?p_id=144093 |
Файлы ресурса | |
|
Полная запись метаданных |
Поле DC |
Значение |
Язык |
dc.contributor.author |
Габдулхакова Аида Габдрахмановна |
ru_RU |
dc.date.accessioned |
2016-01-01T00:00:00Z |
ru_RU |
dc.date.available |
2016-01-01T00:00:00Z |
ru_RU |
dc.date.issued |
2016 |
ru_RU |
dc.identifier.citation |
Meijer L. Modulating Innate and Adaptive Immunity by (R)-Roscovitine: Potential Therapeutic Opportunity in Cystic Fibrosis. / Nelson DJ, Riazanski V, Gabdoulkhakova AG, Hery-Arnaud G, Le Berre R, Loaëc N, Oumata N, Galons H, Nowak E, Gueganton L, Dorothée G, Prochazkova M, Hall B, Kulkarni AB, Gray RD, Rossi AG, Witko-Sarsat V, Norez C, Becq F, Ravel D, Mottier D, Rault G. // J Innate Immun. - 2016. - 8(4): P. 330-49. doi: 10.1159/000444256. |
ru_RU |
dc.identifier.uri |
https://repository.kpfu.ru/?p_id=144093 |
ru_RU |
dc.description.abstract |
J Innate Immun |
ru_RU |
dc.description.abstract |
Journal of innate immunity |
ru_RU |
dc.description.abstract |
(R)-Roscovitine, a pharmacological inhibitor of kinases, is currently in phase II clinical trial as a drug candidate for the treatment of cancers, Cushing's disease and rheumatoid arthritis. We here review the data that support the investigation of (R)-roscovitine as a potential therapeutic agent for the treatment of cystic fibrosis (CF). (R)-Roscovitine displays four independent properties that may favorably combine against CF: (1) it partially protects F508del-CFTR from proteolytic degradation and favors its trafficking to the plasma membrane; (2) by increasing membrane targeting of the TRPC6 ion channel, it rescues acidification in phagolysosomes of CF alveolar macrophages (which show abnormally high pH) and consequently restores their bactericidal activity; (3) its effects on neutrophils (induction of apoptosis), eosinophils (inhibition of degranulation/induction of apoptosis) and lymphocytes (modification of the Th17/Treg balance in favor of the differentiation of anti-inflammator |
ru_RU |
dc.language.iso |
ru |
ru_RU |
dc.subject |
Roscovitine |
ru_RU |
dc.subject |
Seliciclib |
ru_RU |
dc.subject |
TRPC6 |
ru_RU |
dc.subject |
CFTR |
ru_RU |
dc.subject |
Corrector |
ru_RU |
dc.subject |
Cystic fibrosis |
ru_RU |
dc.subject |
Infection |
ru_RU |
dc.subject |
Inflammation |
ru_RU |
dc.subject |
Innate immunity |
ru_RU |
dc.subject |
Pseudomonas aeruginosa
|
ru_RU |
dc.title |
Modulating Innate and Adaptive Immunity by (R)-Roscovitine: Potential Therapeutic Opportunity in Cystic Fibrosis |
ru_RU |
dc.type |
Статьи в зарубежных журналах и сборниках |
ru_RU |
|